All News

pso.PsA_.NPF_.jpg

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

d Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
Stillsnow, Stills, podcast

StillsNow Podcast December 2023 - ACR23 Highlights

d Jack Cush, MD

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.

Read Article
RA ILD RTX lung

Best of 2023: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

d ACR

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Read Article
CSS Storm Cytokine

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

d Jack Cush, MD

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.

Read Article
DMARDs,biologics,RA

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

d Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
ANA.Wikipedia.jpg (keep)

Best of 2023: New Laboratory Insights for the ANA+ Consult

d Jack Cush, MD

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Read Article
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease. https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2023: New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD) https://t.co/5RgA143wLb https://t.co/JZU7ZX3Gty

Links:

Dr. John Cush RheumNow ( View Tweet)

AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/Hw9RECWYg5 https://t.co/A5JMCSpl0D

Links:

Dr. John Cush RheumNow ( View Tweet)
Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/R2TOzSO6cx https://t.co/XY3XEkSCT6

Links:

Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W

Links:

Dr. John Cush RheumNow ( View Tweet)
Chronic Pain Management tools 1 Medication 2 Physical Therapy 3 Cognitive-Behavioral Therapy 4 Mindfulness Meditation 5 Acupuncture 6 Massage 7 Heat/Cold 8 TENS 9 Yoga/Tai Chi 10 Support groups https://t.co/VBvYR8VK16

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves Colchicine for CV Prevention. The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication. https://t.co/g6j9yvl1n2 https://t.co/RUip1o4MYZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown. https://t.co/gsCtfHzn4Z https://t.co/lIaf36epZY

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2023: How Being a Patient Taught Me to Be a Better Doctor Since I can remember, I always wanted to be a doctor. My dad was a trauma surgeon and my mom a nurse. https://t.co/JE4QoJy4jp https://t.co/jrJoqRD30P

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2023: LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2

Links:

Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts #RNL2023 https://t.co/BqZlajMOLK https://t.co/Omui3LWiPi

Links:

Dr. John Cush RheumNow ( View Tweet)
Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/yxujTvbVGp https://t.co/UfOkrJDgcU

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read comprehensive review by Isenberg et al-what Rx works in SLE; review of RCT data on approved & developing drugs: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/4JvbZ6ysWn https://t.co/FePnuTsHhN

Links:

Dr. John Cush RheumNow ( View Tweet)
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/HpOdaXAxff https://t.co/HpOdaXAxff https://t.co/IrjJcxUG9b

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×